GlassScriptPhysician profile
Daniel H Darmadi
NPI 1407849946
$14,300.66
in general payments reported to CMS, 2019-2025
38 companies · $2,862 in 2025
The $2,862 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,932 · 2020: $1,099 · 2021: $2,092 · 2022: $2,377 · 2023: $2,681 · 2024: $1,258 · 2025: $2,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,778 · Education: $22.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,778.28 |
| Education | $22.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,641.85 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $2,059.38 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,782.96 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Gilead Sciences, INC. | $1,451.41 | 2019-2025 | |
| Redhill Biopharma INC. | $756.41 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Celgene Corporation | $750.01 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $544.64 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $383.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $303.19 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $288.31 | 2019-2023 | Linzess |
| Celltrion USA INC. | $257.71 | 2023-2025 | Vegzelma, Yuflyma |
| Intercept Pharmaceuticals, INC. | $253.76 | 2019-2022 | |
| Evoke Pharma, INC. | $231.39 | 2022-2024 | Gimoti |
| Braintree Laboratories, INC. | $226.51 | 2019-2025 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $159.51 | 2024-2025 | Zenpep |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $153.09 | 2019-2025 | Encore 26 |
| Johnson & Johnson Health Care Systems INC. | $142.47 | 2024 | Tremfya |
| Allergan, INC. | $129.33 | 2019 | |
| Romark Laboratories, Lc | $103.34 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $75.77 | 2019 | |
| Pfizer INC. | $59.66 | 2025 | |
| Nestle Healthcare Nutrition INC. | $59.32 | 2022 | |
| Genzyme Corporation | $51.26 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $47.99 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $47.26 | 2021 | |
| Phathom Pharmaceuticals, INC. | $46.11 | 2024 | Voquezna |
| Shire North American Group INC | $38.68 | 2019 | |
| Olympus America INC. | $38.01 | 2024 | Gastrointestinal Videoscope |
| Shionogi INC | $37.29 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $33.98 | 2020 | |
| Ambu INC. | $26.37 | 2021 | |
| Lilly USA, LLC | $26.21 | 2025 | Omvoh |
| Alnylam Pharmaceuticals INC. | $23.62 | 2021 | |
| Inspire Medical Systems, INC. | $23.47 | 2025 | Inspire |
| Vivus LLC | $19.35 | 2025 | Pancreaze |
| Vibrant Gastro, INC. | $16.07 | 2023 | Vibrant Starter Kit |
| Cook Medical LLC | $11.78 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,834.32 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Darmadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.